MedTrace Logo

Human Immunity to MSP-1 in Western Kenya

NCT00138372 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 475

Last updated 2022-01-20

No results posted yet for this study

Summary

This is a study of 125 healthy male and female Kenyan adults aged 18 years and above, and 300 healthy male and female Kenyan infants enrolled at 1 month of age and followed to 3 years of age. Twenty healthy adults (US residents) who have no self-reported history of Malaria exposure, infection or travel to malaria endemic areas of the world will serve as Malaria Naive Negative Controls. The proposed study represents a continuation of molecular and immunologic studies done in human populations describing mechanisms of protection against malaria infection and disease. Human investigation of those experiencing natural exposure to malaria infections are justified since they will eventually be the target population for testing malaria vaccine safety and efficacy.

Conditions

  • Plasmodium Falciparum Malaria

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Case Western Reserve University

    lead OTHER

Principal Investigators

  • James W Kazura, M.D. · Case Western Reserve University

Eligibility

Min Age
1 Month
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2008-09-30
Completion
2013-04-30

Countries

  • Kenya

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00138372 on ClinicalTrials.gov